87 results about "Small Nuclear Ribonucleic Acid" patented technology

invention discloses a kit for a serum micro-ribonucleic acid and the application in the early diagnosing of hepatitis B thereof which belong to the technical field of biotechnological pharmaceutics. The invention provides the combination of the micro-ribonucleic acid used for estimating the physiological and/or pathological states of a normal person, a HBVer and a patient with hepatitis B; the combination comprises all the micro-ribonucleic acids which have differential expression in the serum/plasm of the normal person, the HBVer and the patient with hepatitis B and prepares a diagnosing kit which can be used for the early diagnosing of hepatitis B. The combination and the method can be used for the early detection and nondirective therapy of hepatitis B; besides, the combination and the method have the advantages of high specificity, high efficiency, high sensitivity, low detection cost, convenient material obtaining, and the like. Besides, the samples are easily stored.

The invention relates to a marker for detecting colon and rectum cancer by utilizing 86 specific ribonucleic acids stably existing in the serum/plasma of a human body, as well as a method, a relevant kit and a biological chip for detecting the marker. The method can be used in the aspects of diagnosing and differentially diagnosing the colon and rectum cancer and predicting the generation and the recurrence of the complications of diseases, evaluating the curative effect, screening the active ingredients in drugs, evaluating the drug effect and the like, and has the advantages of wide detection pedigree, high sensitivity and low detection cost, material is convenient for obtainment, samples are easy to store and the like. The method can be widely used for generally surveying the colon and rectum cancer and relevant work and improving low specificity and low sensitivity which are brought by the individual difference difficultly and are difficult to overcome by the single marker, thereby obviously enhancing the clinical detection rate of the colon and rectum cancer and becoming an effective means for early diagnosing the colon and rectum cancer.

The invention provides a pancreatic cancer marker, and a detection method, a kit and a biochip thereof. The pancreatic cancer marker provided by the invention contains 36 kinds of micro ribonucleic acids which stably exist in the serum/plasma of a person receiving the test and can be detected. The invention also provides a kit and a biochip of tools or elements for detecting the pancreatic cancer marker. The combination, the method, the kit and the biochip provided by the invention can be used for auxiliary diagnosis and differential diagnosis of pancreatic cancers, predication of occurrence and recrudescence of disease complications, evaluation of the curative effect, screening of active ingredients of medicaments, evaluation of pesticide effectiveness and the like, and has the advantages of wide detection range, high sensitivity, low detection cost, readily available raw materials, easy storage of samples and the like; and the method is widely applied to work related to the general survey of pancreatic cancers, improves the specificity and sensitivity which are low in the single marker due to individual difference, obviously increases clinical detection rate of pancreatic cancers and becomes an effective method for early diagnosis of pancreatic cancers.

The present invention belongs to the field of biotechnology and is especially one kind of biochip for identifying the cancerization degree of pathological colon based on the specific change of micro RNA. The present invention solves the technological problem of determining one set of precise and simple probe library to lower the making cost of biochip and simplify the making process of biochip. The technological scheme of the present invention includes screening out micro RNA with obvious and stable change in pathological colon with biochip and quantitative PCR and applying the micro RNA as probe on the biochip to form the biochip for detecting colon cancer pathology. The biochip may be used to diagnose early stage colon cancer.

The invention relates to a breast cancer detecting marker by utilizing 16 specific tiny ribonucleic acids steadily existing in blood serum and blood plasma of a human body as well as a detecting method, a kit and a biological chip thereof, and the detecting marker can be used in the aspects of diagnosis and differential diagnosis of breast cancer, occurrence and recurrence forecast as well as efficacy assessment of disease complications, screening and therapeutic evaluation of medicinal active ingredients and the like, and has the advantages of wide detection pedigree, high sensitivity and low detection cost, the materials are conveniently taken, the samples are easy to store and the like. The method can be widely used in related work such as breast cancer census, the defects of low specificity and low sensitivity caused by insuperable individual difference of a single marker can be improved and the clinical detectable rate of the breast cancer is notably improved, and is an effective mean of early breast cancer diagnosis.

The invention discloses a method for identifying micro ribonucleic acid in the blood serum of colon carcinoma patients through a Solexa technique, belongs to the technical field of biological medicine, and particularly relates to the Solexa technique that researches on the micro ribonucleic acid expression in the blood serum and the application of the Solexa technique in colon carcinoma diagnosis. The method for identifying the micro ribonucleic acid in the blood serum of colon carcinoma patients comprises measuring an expression profiling of the micro ribonucleic acid in the blood serum of a colon carcinoma subject by applying the Solexa sequencing method. The Solexa sequencing method has the advantages of wide measuring pedigree, high sensitivity, convenient materials obtaining and easy sample storing, etc., and can be widely used for relevant tasks such as disease census measuring, which can improve low specificity and low sensitivity that are caused by individual difference and are difficult to be overcome by single markers, and remarkably improve the clinical relevance ratio of diseases, and is an effective method for disease diagnosis in early stages.

A method for identifying micro ribonucleic acid (RNA) in the blood serum of a lung cancer patient through Solexa technology belongs to the biological medicine technical field, in particular relating to a Solexa technology for measuring the expression of micro RNA in the blood serum of a lung cancer patient as well as an application of the Solexa technology in clinic diagnosis and therapy such as early diagnosis of lung cancer, curative effect appraisement and drug effect appraisement, etc. The Solexa technology comprises the following steps that: a Solexa sequencing method is used to measure the content of micro RNA in the blood serum of a lung cancer testee; the appraisement of the physiological and/or pathological status of the testee is to carry out lung cancer diagnosis of the testee; and the physiological and/or pathological status of the testee is tested after the testee receives a to-be-tested object. The Solexa sequencing method has the advantages of wide detection pedigree, high sensitivity, low detection cost, convenient material obtaining and easily stored samples, etc.; moreover, the method can be widely used in related operations including lung cancer screening, etc. so as to improve the conditions of low specificity and low sensitivity caused by individual difference which is difficult to be overcome by a single marker; therefore, the method can substantially increase the clinic detection rate of lung cancer, and is an effective way to carry out early diagnosis of lung cancer.

The invention which belongs to the medical field of genetic engineering and reproduction discloses a seminal plasma miRNA marker associated with human non-obstructive azoospermia and an application thereof. The maker is selected from several of hsa-miR-141, hsa-miR-193a-5p, hsa-miR-590-5p and hsa-miR-7-1*. The maker which has specificities and sensitivities to the non-obstructive azoospermia can be used for the preparation of a reagent for non-obstructive azoospermia diagnosis or monitoring, so invasive diagnosis is avoided, repeated detection is realized, and the dynamic monitoring of the obstacle degree of sperm generation can be easily achieved.

The invention belongs to the technical field of biotechnology, and discloses a miRNA combination used for detecting esophageal squamous cell carcinoma and application thereof. The miRNA combination comprises miR-22, miR-127-3p, miR-148b and miR-223, and the miRNA combination can further comprise one or more of miR-10a, miR-100 and miR-133a. A kit comprises a probe combination of the miRNAs. The miRNA combination and the probe combination thereof provided by the invention can be used for detecting the esophageal squamous cell carcinoma, and can be used as a diagnosis marker for improving the accuracy of detection, improving the insuperable low specificity and low sensitivity, caused by individual difference, of a single marker, and improving a clinical detectable rate remarkably by combining other detection indicators and clinical symptoms of a patient, so the miRNA combination and the probe combination thereof become an effective means for early diagnosis of the esophageal squamous cell carcinoma. Due to the adoption of the miRNA combination, a noninvasive serological test is adopted so as to bring convenience to clinical promotion.

The invention belongs to the fields of gene engineering and clinical medicine, and discloses a plasma micro-ribonucleic acid (miRNA) marker related with a human Hirschsprung's disease and application of the miRNA marker. The marker is selected from multiple kinds of hsa-miR-34b, hsa-miR-31*, hsa-miR-141 and hsa-miR-194. The marker has specificity and sensitivity on the Hirschsprung's disease, canbe used for preparing a reagent for diagnosing or monitoring the Hirschsprung's disease, can avoid invasive diagnosis, can be used for screening and diagnosis at the early stage, can be repeatedly detected, and is easy in dynamic monitoring.

The invention belongs to the field of gene engineering and reproductive medicines, and discloses a seminal plasma micro ribonucleic acid marker related to spermatogenesis deficiency and application thereof. The marker is selected from one or more of SEQ ID No.2, SEQ ID No.3 and SEQ ID No.4, has specificity and sensitivity to the spermatogenesis deficiency, can be used for preparing a reagent for diagnosing or monitoring the spermatogenesis deficiency, can avoid invasive diagnosis, can carry out repeated detection, and is easy to dynamically monitor the degree of the spermatogenesis deficiency.

The invention discloses miR-106b-5p, a detection primer thereof and application of the antisense nucleotide sequence thereof in the fields of ischemic cerebral stroke diagnosis and treatment, and belongs to the field of application of micro ribonucleic acid. The sequence of a reverse transcription primer in the detection primer of the miR-106b-5p is 5'-CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGATCTGCAC-3'. The antisense nucleotide sequence of the miR-106b-5p is 5'-AUCUGCACUGUCAGCACUUUA-3'. The miR-106b-5p, the detection primer thereof and the antisense nucleotide sequence thereof are associated with acute ischemic cerebral strokes, the miR-106b-5p can become an auxiliary index of acute ischemic cerebral stroke clinical detection, and a therapeutic target is provided for prevention of the disease. The miR-106b-5p has the advantages of being good in treatment effect, easy to operate, free of toxic and side effects and the like.

The invention belongs to the technical field of biology and relates to an early pancreatic cancer marker and a detection method thereof. A biological micromolecule which can be used for early pancreatic cancer molecular diagnosis and treatment is developed on the basis of expression intensity differences of various micro ribonucleic acids in early pancreatic cancer cells. The early pancreatic cancer marker has advantages of wide detection pedigree, high sensitivity, high specificity, low detection cost, convenience in material acquisition, easiness in sample storage and the like. The method can be widely applied to pancreatic cancer early screening and prognosis and the like, low specificity and low sensitivity due to hard-to-overcome individual differences caused by intrinsic instabilityof single markers or biomarkers clinically and extensively applied at present are improved, the early pancreatic cancer clinical detection rate is remarkably increased, the pancreatic cancer misdiagnosis rate and missed diagnosis rate are decreased, and the method is an effective means of early pancreatic cancer detection.

The invention provides the combination of microRNAs used for evaluating the liver cancer condition of a subject and contains microRNAs which exist stably and are detectable in the serum/plasma of the subject. A method for evaluating the liver cancer condition of the subject comprises a step of measuring the microRNAs which exist stably and are detectable in the serum/plasma of the subject. A kit used for evaluating the liver cancer condition of the subject contains a tool for measuring the microRNAs which exist stably and are detectable in the serum/plasma of the subject. A biochip for evaluating the liver cancer condition of the subject contains a component for measuring the microRNAs which exist stably and are detectable in the serum/plasma of the subject. The novel technology can be used in the aspects of the diagnosis and the differential diagnosis, the prognosis of the generation and the recurrence of the disease complication and the therapeutic effect evaluation of liver cancer, the screening and the pharmacological effect evaluation of medicinal active ingredients and the like.

The invention relates to 17 specific micro ribonucleic acids serving as cervical cancer detection markers, existing in human serum/plasma and capable of being detected, and a method, a related kit and a biochip for detecting the markers. The markers can be used for diagnosis and identification of cervical cancer, prediction of occurrence and relapse of disease complications, curative effect evaluation, screening of medicinal active ingredients, medicinal effect evaluation and the like, have the advantages of broad detection spectrum, high sensitivity, low detection cost, convenience for taking materials and the like, and are easy to store samples. The method can be widely used for related operations such as cervical cancer general investigation and the like, improves low specificity and low sensitivity caused by individual difference difficult to be overcome by single marker, remarkably improves the clinical detection rate of the cervical cancer, and becomes an effective means for early diagnosing the cervical cancer.

Compounds of formula (I), wherein the variables of the formula are as defined in the present disclosure, advantageously inhibit or block the biological activity of picornavirus 3C protease. These compounds, and pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with one or more picornaviruses, such as RVP. Intermediates and synthetic methods for preparing such compounds are also described.

The invention discloses a detection card for rapidly detecting micro ribonucleic acid (miRNA). The detection card comprises a sample pad, a nanomaterial pad, a nitrocellulose membrane and an absorbent pad, wherein the nitrocellulose membrane is a detection card substrate, a sample injection zone, a blank control zone and a sample detection zone are distributed on the detection card substrate, the sample injection zone is communicated with the sample detection zone, the blank control zone and the sample detection zone are modified with probes having miRNA sequences complementary to to-be-detected miRNA, one ends of the probes are connected with the detection card substrate, and the other ends of the probes carry fluorescent groups. The invention also discloses a preparation method of the detection card. The invention also discloses a kit for rapidly detecting the miRNA associated with lung cancer. The invention also discloses application of the detection card and the detection kit. The detection card has relatively high detection sensitivity on miRNA associated with lung cancer and can simultaneously detect a plurality of miRNAs without PCR, the clinical diagnostic specificity is improved and the detection card meets application requirements of screening, diagnosis of lung cancer, determination of treatment effect and follow-up visit.

The present invention discloses an anti-hepatitis B virus minute ribonucleic acid interference molecule. It is characterized by that two double-stranded DNA oligonucleotides with gene target inactivation action can respectively act on X protein gene and coat protein gene of HBV, in which anti-HBV mi RNAi acting on X protein and coat protein of HBV respectively has DNA sequence structures shown by sequence-1 and sequence-2 in sequence table, and their action target points respectively have DNA sequence structures shown by sequence-3 and sequence-4 in the sequence table. Besides, said invention also provides the designing method of said anti-hepatitis B virus minute ribonucleic acid interference molecule and its concrete steps.

The invention belongs to the field of gene engineering, and discloses mitochondrion correlation serum micro ribonucleic acid serving as markers of human obesity occurrence and application thereof. The markers are some miRNA which is mitochondrion correlation miRNA and is selected from hsa-miR-141-3p, hsa-miR-196a-5p, hsa-miR-210-3p, hsa-miR-378a-3p, hsa-miR-484 and hsa-miR-499a-5p. Obesity cases and normal body weight can be well contrasted and separated, and the markers can be used for preparing obesity diagnosing or monitoring kits.

The invention provides an application of miRNA marker hsa-miR-486-5p. A serum micro ribonucleic acid marker provided by the invention as a CWP early diagnosis marker has the advantages that serum miRNAs are novel biomarkers, are different from traditional biomarkers, and have the advantages of being stable, minimally invasive, easy to detect, accurate to quantify and the like, the sensitivity and the specificity of disease diagnosis are greatly improved, a new situation is created for early diagnosis of CWP by successful development of micromolecular RNA biomarkers, and reference is provided for development of other disease biomarkers.

The invention discloses a micro ribonucleic acid detection method based on a microfluidic bead array chip and a DNA polymerase-mediated primer extension technology. According to the detection method, a micro ribonucleic acid capture probe modified by biotin is fixed to the surface of an avidin-modified microsphere through a biotin-avidin bonding method to form a functionalized microsphere; the functionalized microsphere is fixed in a micro chamber corresponding to a detection zone of a microfluidic chip so as to form the microfluidic bead array detection chip; then a sample solution containing micro ribonucleic acid is allowed to flow into the microfluidic bead array detection chip, then to flow into a DNA polymerase solution and a biotinylation extension substrate, and finally to flow into a quantum dot labeled by the avidin; and surface fluorescence of the microsphere after the micro ribonucleic acid flows into is calculated to perform qualitative operation and quantification. The method can detect the micro ribonucleic acid with high sensitivity and high specificity and achieves quantification analysis of specificity and sensitivity of the micro ribonucleic acid in a total RNA sample.

The invention relates to a symbolic micro RNA marker for detecting a spermatogenic failure passage effect and application thereof, belongs to the field of biotechnology and reproductive medicine, and discloses a micro RNA (miRNA) marker for detecting a spermatogenic failure passage effect and application thereof. The marker is a plurality selected from a group consisting of rho-miR-1-3p, rho-miR-124-3p and rho-miR-190a-5p. The marker has specificity and sensitivity for monitoring the spermatogenic failure passage effect, provides a reliable detection basis and quick detection method for diagnosis monitoring of the spermatogenic failure passage effect and has important application values.

The invention discloses a method for improving cattle cloning efficiency by micro ribonucleic acid. bta-miR-125b mimic is added into electrical fusion solution of somatic cell nucleus transfer and can be effectively led into an embryo, the histone H3K9me3 epigenetic modification level of a somatic cell cloning embryo in a zygotic activation period can be effectively weakened while secondary damage of transfection is avoided, and the developmental rate and the quality of a cattle somatic cell cloning blastaea can be obviously improved.